This application is a U.S. National Stage of PCT/GB2012/052950, filed Nov. 29, 2012; which claims the benefit of priority of GB1120693.5; filed Dec. 1, 2011; each of which is incorporated herein be reference in their entirety.
The present invention relates to a device and kit for treating a wound with a dressing and vacuum.
Vacuum has been used to increase blood flow to wound tissue and to remove exudate from the wound site. In general vacuum treatment uses a device comprising a cover for sealing about the outer perimeter of the wound, under which a vacuum is established to act on the wound surface. The vacuum applied to the wound surface accelerates healing of chronic wounds. A screen of open cell foam material or gauze is typically used under the cover to provide the space in which the vacuum is formed and to reduce tissue ingrowth. Sufficient vacuum is applied for a suitable duration to promote tissue migration in order to facilitate the closure of the wound. Suitable vacuum is between about 0.1 and 0.99 atmospheres. The vacuum can be substantially continuous or can be cyclic with the application of vacuum for alternating periods of application and nonapplication.
Many common conventional and advanced wound contact dressings have shortcomings particularly for use in suction wound therapy. In an example, gauze and other similar flat fabric materials are commonly used as wound dressings. When gauze is in contact with a wound it becomes wet with exudate and collapses into the wound. New tissue growth can engulf the gauze making it difficult and painful to remove from the wound. When foam is in contact with a wound and vacuum is applied, the foam can collapse and in-growth of tissue can occur into the collapsed cell structure of the foam. In order to overcome this problem relatively rigid perforated sheets have been used to contact the wound. However, they are not sufficiently flexible and conformable to comfortably and adequately conform to wound surfaces that are often irregular in contour. A dressing having such an inflexible or rigid structured material or wound contact layer can cause unnecessary pain and discomfort to a patient.
In WO 2006/052839 a vacuum wound dressing is described which is a fibrous blend or fibrous material that forms a cohesive gel when wetted with wound exudate. The dressing is in the form of a non-woven fibrous mat.
A wound dressing for use in vacuum wound therapy preferably has some or all of the following characteristics and properties:
We have found that it is possible to provide a gel-forming wound dressing with many of the above desirable properties and which overcomes some of the problems of tissue ingrowth identified above while filling the wound and allowing exudate to flow out of the wound site when a vacuum is applied.
Accordingly the invention provides a wound dressing for use in vacuum wound therapy comprising a wound contact layer which is an open structure comprising a yarn which comprises gel-forming filaments or fibres, the structure having a porosity which allows exudate to flow through it.
It has been found that strain imposed on the tissue by the vacuum is believed to stimulate new tissue growth and assist healing. The porosity present in the open structure of the dressing according to the invention is believed to facilitate the application of strain to the tissue of the wound.
The open structure can be in the form of a net knitted, woven or embroidered from a yarn comprising gel-forming filaments or fibres. By the term yarn is meant a thread or strand of continuous filament or staple fibres. Alternatively the open structure can be first knitted, woven or embroidered from a textile yarn which is then chemically modified to impart gel-forming properties to it. For instance, the yarn can be a cellulose yarn which is knitted or woven to form the open structure and is then chemically modified to give the fibres greater absorbency and gelling properties.
By gel forming fibres is meant hygroscopic fibres which upon the uptake of wound exudate become moist slippery or gelatinous and thus reduce the tendency for the surrounding fibres to adhere to the wound. The gel forming fibres can be of the type which retain their structural integrity on absorbtion of exudate or can be of the type which lose their fibrous form and become a structureless gel. The gel forming fibres are preferably spun sodium carboxymethylcellulose fibres, chemically modified cellulosic fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres, or other polysaccharide fibres or fibres derived from gums. The cellulosic fibres preferably have a degree of substitution of at least 0.05 substituted groups per glucose unit. The gel forming fibres preferably have an absorbency of at least 2 grams 0.9% saline solution per gram of fibre (as measured by the free swell absorbency method BS EN 13726-1:2002 Test methods for primary wound dressings—Part 1: Aspects of absorbency, Method 3.2 free swell absorptive capacity).
Preferably the gel forming fibres have an absorbency of at least 10 g/g as measured in the free swell absorbency method, more preferably between 15 g/g and 25 g/g.
The dressing may for instance comprise non gel forming fibres and in particular textile fibres such as Tencel, cotton or viscose and may comprise lycra or other elastic fibre. Preferably the textile fibres have an absorbency of less than 10 g/g as measured by the free swell method and more preferably less than 5 g/g.
The pore size of the dressing in part determines the strain placed on the wound when suction is applied. The strain is also determined by the uniformity of the dressing over the area treated. The maximum strain and the uniformity of its application will therefore depend not only on the pore sixe of the open structure but also on the linear density of the yarn used to make the dressing. Maximum strain can be achieved by increasing the pore size or increasing the yarn linear density. Uniformity is increased by decreasing the pore size and decreasing the yarn linear density. We have found that acceptable strain is placed on the wound where the structure preferably has a pore size of between 0.5 mm2 to 5.0 mm2, more preferably between 3.0 mm2 to 4.0 mm2 and the yarn has a linear density of 20 tex to 40 tex.
The open structure can be in the form of a net with yarn joined at intervals to form a set of meshes or the open structure can be knitted with a pore sizes as mentioned above.
An advantage of such an open structure is that it is easily folded or crumpled to fit the wound and pack the wound site. Due to the structure, the dressing still allows exudate to pass through it when a vacuum is applied to the wound even though the dressing may not be co-planar with the wound bed. The conformability of the open structure allows all parts of the wound to be contacted with a similar dressing structure so that for instance the sides of the wound are contacted by the open structure as well as the wound bed.
In a further embodiment the invention provides a device for vacuum wound therapy comprising a wound dressing which is an open structure comprising a yarn of gel-forming filaments or fibres, the structure having a porosity which allows exudate to flow through it;
The open structure of the dressing of the invention can be made by first forming a yarn of gelling fibres. This may be done in various ways. For example gel forming fibres, which are for instance any of those mentioned above or can be modified cellulose, or carboxymethyl cellulose or alginate, can be spun into yarns comprising various blends of gel-forming staple fibres and textile fibres. The spinning may be done by first carding the fibres in the blend and spinning a yarn from the carded blend.
We have found that particularly suitable yarns can be formed by rotor spinning or open end spinning. In such a process, staple gel-forming fibres are blended with textile fibres and carded to produce a continuous web. The web is condensed to produce a card sliver and then rotor spun. In rotor spinning, a high speed centrifuge is used to collect and twist individual fibres into a yarn. The yarns produced from this technique have the characteristics of sufficient tensile strength to enable them to be further processed using knitting or weaving machinery.
A further embodiment of the invention provides a process for making a yarn comprising gel-forming fibres comprising the steps of:
Yarns produced by this method preferably comprise from 30% to 100% by weight gel-forming fibres and 0% to 70% by weight textile fibres. More preferably the yarns comprise from 50% to 100% by weight of gel-forming fibres with the balance of textile fibres and most preferably from 60% to 100% by weight of gel-forming fibres.
The fibres present in the spun yarn preferably have a staple length of 30 to 60 mm, more preferably 40 to 55 mm and most preferably 45 to 55 mm.
A yarn made according to the processes of the present invention need not contain textile fibres enabling structures to be produced which consist wholly of gel-forming fibres.
A gelling yarn can be produced using a spun yarn consisting of natural cellulose fibres or solvent spun cellulose staple fibres or a blend of cellulose fibres and other textile fibres or by using a filament yarn of solvent spun cellulose which is then converted to chemically modify the yarn to produce gelling properties. For example, Lyocell yarns can be used as a starting material and converted in a kier process to impart gel-forming behaviour to the yarn.
Yarns made according to the processes of the present invention preferably have a dry tensile strength of at least 10 cN/tex, preferably from 10 to 40 cN/tex and most preferably from 16 to 35 cN/tex as measured by British Standard ISO 2062 2009.
Alternatively the open structure of the dressing of the invention can be made by weaving using a textile yarn and the resulting fabric then converted to impart gel-forming behaviour to it to form an open structure of gel-forming fibres.
It is also possible to warp or weft knit an open structure using a textile yarn such as Lyocell and then convert the resulting fabric to make the wound dressing of the invention. Further it is possible to embroider an open structure in textile yarn onto a support film which is then removed for instance by washing and the resulting structure converted to form an open structure comprising a yarn of gel-forming fibres.
In a further aspect the invention provides a process for making an open structure or net of gel-forming fibres by:
A preferred method of converting the yarns or fabrics is described in WO 00/01425. For example the yarns or fabrics can be carboxymethylated by pumping a reaction fluid through the reaction vessel and therefore the cellulosic materials at 65° C. for 90 minutes. The reaction fluid is a solution of an alkali (typically sodium hydroxide) and sodium monochloroacetate in industrial denatured alcohol. After the reaction time, the reaction is neutralised with acid and washed before being dried in a laboratory oven for 1 hour at 40° C.
Preferred embodiments of the invention are illustrated in the drawings in which:
The invention is illustrated by the following examples.
Spinning Yarn from Staple Gel-Forming Fibres
Lyocell fibres and carboxymethyl cellulose staple fibres in blends of 50:50, 60:40 and 70:30 CMC:Lyocell were made by carding on a Trutzschler cotton card and spinning the resulting sliver at a twist of 650 turns/meter.
Converting a Textile Yarn to a Gel-Forming Yarn
Yarns were converted in the laboratory using a mini kier. In both trials, staple and filament lyocell yarns were converted. The yarns used for the conversion were staple 33 Tex Tencel®; HF-2011/090; and 20 Tex filament lyocell batches HF-2011/051 (trial 1) and HF-2011/125 (trial 2). Tencel® is a Lenzing owned, trademarked brand of lyocell and the Tencel® yarn used was a spun staple yarn. The filament lyocell was supplied by Acelon chemicals and Fiber Corporation (Taiwan) via Offtree Ltd.
The advantages of converting a yarn are that complete cones of yarn could potentially be converted in one relatively simple process, and the processing of gelling fibres is avoided, thus reducing the number of processing steps required and damage to the fibres.
Trial 1—Yarn Wrapped Around Kier Core
In this trial, Tencel® yarn was tightly wrapped around the perforated core of the kier using an electric drill to rotate the core and pull the yarn from the packages for speed. This meant that the yarn was wrapped tightly around the core under tension.
The yarn was converted by a process as described in WO 00/01425 in which carboxymethylation was carried out by pumping fluid through the kier and therefore the cellulosic materials at 65 C. for 90 minutes. The reaction fluid was a solution of an alkali (typically sodium hydroxide) and sodium monochloroacetate in industrial denatured alcohol. After the reaction time, the reaction was neutralised with acid and washed before being dried in a laboratory oven for 1 hour at 40 C.
The conversion was successful and both staple and filament gelling yarns were produced; HF-2011/103 and HF-2011/105 respectively. Due to the tight and uneven wrapping of the staple yarn around the core, it had to be removed using a scalpel which left multiple short lengths (approximately 14 cm) of the converted yarn.
Trial 2—Small Yarn Hanks
The aim of the second trial was to produce longer lengths of converted yarns for testing hence a small hank was made of each the staple and filament lyocell yarns by hand and these were placed between layers of fabric for the conversion.
The yarn was converted by placing the hanks in a kier and converting to form a gel-forming fibre yarn as described above for Trial 1.
The conversion was successful and both staple and filament gelling yarns were produced; HF-2011/146 and HF-2011/147 respectively.
Yarn Summary
Results from Examples 1 and 2
With the exception of HF-2011/051, all of the yarns were tested for wet and dry tensile strength. Adaptations were made to the standard method BS EN ISO 2062:2009; “Textiles—Yarns from packages: Determination of single-end breaking force and elongation at break using constant rate of extension (CRE) tester”. A Zwick tensile testing machine was used with a gauge length of 100 mm. The test uses a 100N or 20N liad cell to exert a constant rate of extension on the yarn until the breaking point is reached. Wet tensile testing was measured by wetting the samples with 0.2 ml of solution A in the central 3 to 4 cm of each yarn and leaving for 1 minute. The wetted sample was then placed in the jaws of the Zwick and clamped shut. Tensile strength was tested as the yarns produced need to be strong enough to withstand the tensions and forces applied during knitting, weaving and embroidery.
Tensile Strength
The results showed that all of the yarns were stronger when they were dry than when they were wet, with HF-2011/108, the 70:30 gelling yarn, showing the largest proportional strength decrease.
Of the yarns tested, HF-2011/108 was the weakest yarn both when wet and dry with tensile strengths of 12.4 and 3.4 cN/Tex respectively, despite containing 30% lyocell fibres. As this was the weakest yarn, but it was successfully weft knitted; HF-2011/120 and woven; HF-2011/169 into fabrics, it is believed that all of the other yarns would also be strong enough to be converted into fabrics.
Both approaches successfully produced gelling yarns.
Producing Open Structures from Gel-Forming Yarn
A yarn was produced with a 2/12 s worsted count consisting of 60% CMC fibres and 40% viscose fibres, each with a staple length of ˜40 mm and the fibres were blended at the fibre stage. The yarn was produced using a worsted system and two 12 count strands were plied together. When dry, the yarn felt soft and the plying was clear as the two strands wrapped around each other. On wetting with Solution A, the yarn gelled and swelled to form a thicker yarn, and the plying became more pronounced.
A sample was made using this yarn on a warp knitting/stitch bonding machine and was hydrated with Solution A.
The sample structure was knitted with Tencel warp yarns and gelling yarn wefts in a net-like arrangement, which is especially visible when the structure is opened by gentle stretching, as shown in
A yarn comprising gel forming fibres was produced by the method of example 3. Using this yarn a fabric was knitted using Tencel warps and gelling yarn weft insertion. The weft yarns were inserted in such a way that they became locked in due to the pattern of knitting. This material has the weft yarn path notation of 0-1/1-1/1-2/2-3/3-2/2-1/1-2//. The material felt quite thin and when wet, it gels but seems to hold fluid on its surface.
Producing Open Structures from a Textile Yarn
Using a Tajima TMEX-C1201 embroidery machine fabrics were produced on a PVA film from lyocell thread (on the bobbin and as the top thread).
The film was removed by washing in warm tap water in a sink using lots of agitation until the film looked to have been removed. The samples were air dried on the bench The fabrics were converted by a process as described in WO 00/01425 and detailed in Example 2.
Warp Knitting to Produce a Locked in Structure.
To produce a fully locked in structure, a warp knitted fabric without any weft inlays is preferred. In the following example (
Weaving
Open plain weave structures have been produced on a Northrop loom, using a gelling yarn previously described, HF-2011/108 to produce fabric HF-2011/169. And by using a Tencel spun yarn HF-2011/090 and converting at the fabric stage, to produce fabric HF-2011/136. The structure uses a warp density of 7.8 ends/cm and a weft density of 5.5 picks/cm.
To produce a locked in woven sample, leno weaving is used. Leno weaving is a form of weaving in which warp threads are made to cross one another between the picks. As the warp yarns cross one another they are able to hold the weft yarns in place so little movement occurs within the structure. When the sample is cut theoretically the yarns should not be able to be removed as the free end is held in place by multiple warps within the rest of the structure. The leno can be applied to all or some of the yarns within the fabric.
Number | Date | Country | Kind |
---|---|---|---|
1120693 | Dec 2011 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/GB2012/052950 | 11/29/2012 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2013/079947 | 6/6/2013 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4984570 | Langen | Jan 1991 | A |
5731083 | Bahia et al. | Mar 1998 | A |
6268544 | Court | Jul 2001 | B1 |
6458460 | Griffiths et al. | Oct 2002 | B1 |
6471982 | Lydon et al. | Oct 2002 | B1 |
6548730 | Patel et al. | Apr 2003 | B1 |
6656496 | Kilpadi | Dec 2003 | B1 |
7951124 | Boehringer et al. | May 2011 | B2 |
10016537 | Menon et al. | Jul 2018 | B2 |
10046096 | Askem et al. | Aug 2018 | B2 |
10076447 | Barta et al. | Sep 2018 | B2 |
10143784 | Walton et al. | Dec 2018 | B2 |
10426670 | von Blucher et al. | Oct 2019 | B2 |
10426747 | Johnson | Oct 2019 | B2 |
10426875 | Blott et al. | Oct 2019 | B2 |
10434015 | Taylor et al. | Oct 2019 | B2 |
10434142 | Niazi et al. | Oct 2019 | B2 |
10434210 | Olson et al. | Oct 2019 | B2 |
10434284 | Hanson et al. | Oct 2019 | B2 |
D866756 | Allen et al. | Nov 2019 | S |
10463773 | Haggstrom et al. | Nov 2019 | B2 |
10470933 | Riesinger | Nov 2019 | B2 |
10470936 | Wohlgemuth et al. | Nov 2019 | B2 |
10473345 | Barta et al. | Nov 2019 | B2 |
10485707 | Sexton | Nov 2019 | B2 |
10485906 | Freedman et al. | Nov 2019 | B2 |
10492956 | Zamierowski | Dec 2019 | B2 |
10493184 | Collinson et al. | Dec 2019 | B2 |
10493185 | Stokes et al. | Dec 2019 | B2 |
10500103 | Crolzat et al. | Dec 2019 | B2 |
10500173 | Yang et al. | Dec 2019 | B2 |
10500301 | Laurensou | Dec 2019 | B2 |
10500302 | Holm et al. | Dec 2019 | B2 |
10506928 | Locke et al. | Dec 2019 | B2 |
10507141 | Allen et al. | Dec 2019 | B2 |
10532137 | Pratt et al. | Jan 2020 | B2 |
10532194 | Locke et al. | Jan 2020 | B2 |
10537657 | Phillips et al. | Jan 2020 | B2 |
10542936 | Goldberg et al. | Jan 2020 | B2 |
10543133 | Shaw et al. | Jan 2020 | B2 |
10543293 | Suschek | Jan 2020 | B2 |
10555838 | Wu et al. | Feb 2020 | B2 |
10555839 | Hartwell | Feb 2020 | B2 |
10556044 | Robinson et al. | Feb 2020 | B2 |
10561536 | Holm et al. | Feb 2020 | B2 |
10568767 | Addison et al. | Feb 2020 | B2 |
10568768 | Long et al. | Feb 2020 | B2 |
10568771 | MacDonald et al. | Feb 2020 | B2 |
10576037 | Harrell | Mar 2020 | B2 |
10576189 | Locke et al. | Mar 2020 | B2 |
10589007 | Coulthard et al. | Mar 2020 | B2 |
10610415 | Griffey et al. | Apr 2020 | B2 |
10610623 | Robinson et al. | Apr 2020 | B2 |
10618266 | Wright et al. | Apr 2020 | B2 |
10624984 | Courage et al. | Apr 2020 | B2 |
10625002 | Locke et al. | Apr 2020 | B2 |
10632019 | Vitaris | Apr 2020 | B2 |
10632224 | Hardy et al. | Apr 2020 | B2 |
10639206 | Hu et al. | May 2020 | B2 |
10639404 | Lichtenstein | May 2020 | B2 |
10653562 | Robinson et al. | May 2020 | B2 |
10653810 | Datt et al. | May 2020 | B2 |
10653823 | Bharti et al. | May 2020 | B2 |
10660799 | Wu et al. | May 2020 | B2 |
10660992 | Canner et al. | May 2020 | B2 |
10660994 | Askem et al. | May 2020 | B2 |
10667955 | Allen et al. | Jun 2020 | B2 |
10667956 | Van Holten et al. | Jun 2020 | B2 |
10682258 | Manwaring et al. | Jun 2020 | B2 |
10682259 | Hunt et al. | Jun 2020 | B2 |
10682318 | Twomey et al. | Jun 2020 | B2 |
10682386 | Ellis-Behnke et al. | Jun 2020 | B2 |
10687983 | Dahlberg et al. | Jun 2020 | B2 |
10687985 | Lee et al. | Jun 2020 | B2 |
10688215 | Munro et al. | Jun 2020 | B2 |
10688217 | Hanson et al. | Jun 2020 | B2 |
10744040 | Kazala, Jr. et al. | Jun 2020 | B2 |
RE48117 | Albert et al. | Jul 2020 | E |
10702419 | Locke et al. | Jul 2020 | B2 |
10702420 | Hammond et al. | Jul 2020 | B2 |
10703942 | Tunius | Jul 2020 | B2 |
10709760 | Gronberg et al. | Jul 2020 | B2 |
10709883 | Spector | Jul 2020 | B2 |
10716711 | Locke et al. | Jul 2020 | B2 |
10716874 | Koyama et al. | Jul 2020 | B2 |
10729590 | Simmons et al. | Aug 2020 | B2 |
10736787 | Hannigan et al. | Aug 2020 | B2 |
10736788 | Locke et al. | Aug 2020 | B2 |
10736985 | Odermatt et al. | Aug 2020 | B2 |
10743900 | Ingram et al. | Aug 2020 | B2 |
10744041 | Hartwell | Aug 2020 | B2 |
10744237 | Guidi et al. | Aug 2020 | B2 |
10744238 | Guidi et al. | Aug 2020 | B2 |
10744240 | Simmons et al. | Aug 2020 | B2 |
10751442 | Bonnefin et al. | Aug 2020 | B2 |
10751452 | Topaz | Aug 2020 | B2 |
10758423 | Pigg et al. | Sep 2020 | B2 |
10758424 | Blott et al. | Sep 2020 | B2 |
10758425 | Blott et al. | Sep 2020 | B2 |
10758426 | Eddy | Sep 2020 | B2 |
10758651 | Blott et al. | Sep 2020 | B2 |
10765561 | Lattimore et al. | Sep 2020 | B2 |
10765783 | Locke et al. | Sep 2020 | B2 |
10772767 | Bjork et al. | Sep 2020 | B2 |
10780203 | Coulthard et al. | Sep 2020 | B2 |
10792191 | Robinson et al. | Oct 2020 | B2 |
10792192 | Tout et al. | Oct 2020 | B2 |
10792337 | Leung et al. | Oct 2020 | B2 |
10792404 | Hu et al. | Oct 2020 | B2 |
10792482 | Randolph et al. | Oct 2020 | B2 |
20020129596 | Driggars | Sep 2002 | A1 |
20060155260 | Blott et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20070066945 | Martin et al. | Mar 2007 | A1 |
20070185426 | Ambrosio et al. | Aug 2007 | A1 |
20070219512 | Heaton et al. | Sep 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070239078 | Jaeb | Oct 2007 | A1 |
20090234307 | Vitaris | Sep 2009 | A1 |
20090259203 | Hu et al. | Oct 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20100015208 | Kershaw et al. | Jan 2010 | A1 |
20100030178 | MacMeccan et al. | Feb 2010 | A1 |
20100042034 | Riesinger | Feb 2010 | A1 |
20100125233 | Edward et al. | May 2010 | A1 |
20100125258 | Coulthard et al. | May 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100185163 | Heagle | Jul 2010 | A1 |
20100298790 | Guidi et al. | Nov 2010 | A1 |
20110015595 | Robinson et al. | Jan 2011 | A1 |
20110028918 | Hartwell | Feb 2011 | A1 |
20110112457 | Holm et al. | May 2011 | A1 |
20110178451 | Robinson et al. | Jul 2011 | A1 |
20110213319 | Blott | Sep 2011 | A1 |
20110224593 | Tunius | Sep 2011 | A1 |
20110224630 | Simmons et al. | Sep 2011 | A1 |
20110230849 | Coulthard et al. | Sep 2011 | A1 |
20110251566 | Zimnitsky et al. | Oct 2011 | A1 |
20110257572 | Locke et al. | Oct 2011 | A1 |
20110257573 | Hong et al. | Oct 2011 | A1 |
20110275972 | Rosenberg | Nov 2011 | A1 |
20110282309 | Adie et al. | Nov 2011 | A1 |
20120071845 | Hu et al. | Mar 2012 | A1 |
20120130332 | Cotton et al. | May 2012 | A1 |
20120136325 | Allen et al. | May 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20120276183 | Bradford | Nov 2012 | A1 |
20130053795 | Coulthard et al. | Feb 2013 | A1 |
20130123728 | Pratt et al. | May 2013 | A1 |
20130226063 | Taylor et al. | Aug 2013 | A1 |
20140005618 | Locke et al. | Jan 2014 | A1 |
20140074053 | Locke et al. | Mar 2014 | A1 |
20140188060 | Robinson et al. | Jul 2014 | A1 |
20140194838 | Wibaux et al. | Jul 2014 | A1 |
20140200532 | Robinson et al. | Jul 2014 | A1 |
20140236112 | Von Wolff et al. | Aug 2014 | A1 |
20140256925 | Catchmark et al. | Sep 2014 | A1 |
20140276499 | Locke et al. | Sep 2014 | A1 |
20140296804 | Hicks et al. | Oct 2014 | A1 |
20140308338 | Nierle et al. | Oct 2014 | A1 |
20140309574 | Cotton | Oct 2014 | A1 |
20140323999 | Bonnefin et al. | Oct 2014 | A1 |
20150018433 | Leipzig et al. | Jan 2015 | A1 |
20150057624 | Simmons et al. | Feb 2015 | A1 |
20150071985 | Walker et al. | Mar 2015 | A1 |
20150079152 | Wuollett et al. | Mar 2015 | A1 |
20150094674 | Pratt et al. | Apr 2015 | A1 |
20150104486 | Bonnefin et al. | Apr 2015 | A1 |
20150112311 | Hammond et al. | Apr 2015 | A1 |
20150119831 | Robinson et al. | Apr 2015 | A1 |
20150119834 | Locke et al. | Apr 2015 | A1 |
20150141941 | Allen et al. | May 2015 | A1 |
20150148785 | Kleiner | May 2015 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20150245949 | Locke et al. | Sep 2015 | A1 |
20150246164 | Heaton et al. | Sep 2015 | A1 |
20150250979 | Loske | Sep 2015 | A1 |
20150265741 | Duncan et al. | Sep 2015 | A1 |
20150265743 | Hanson et al. | Sep 2015 | A1 |
20150320901 | Chandrashekhar-Bhat et al. | Nov 2015 | A1 |
20160008293 | Shi et al. | Jan 2016 | A1 |
20160051724 | Sahin et al. | Feb 2016 | A1 |
20160067107 | Cotton | Mar 2016 | A1 |
20160100987 | Hartwell et al. | Apr 2016 | A1 |
20160106878 | Yang et al. | Apr 2016 | A1 |
20160106892 | Hartwell | Apr 2016 | A1 |
20160166422 | Karim et al. | Jun 2016 | A1 |
20160193244 | Ota et al. | Jul 2016 | A1 |
20160222548 | Agboh | Aug 2016 | A1 |
20160271178 | Hauser et al. | Sep 2016 | A1 |
20160287743 | Andrews | Oct 2016 | A1 |
20170049111 | Patton et al. | Feb 2017 | A1 |
20170189237 | Locke et al. | Jul 2017 | A1 |
20190293881 | Ramjit et al. | Oct 2019 | A1 |
20190298577 | Locke et al. | Oct 2019 | A1 |
20190298578 | Shulman et al. | Oct 2019 | A1 |
20190298582 | Addison et al. | Oct 2019 | A1 |
20190307611 | Askem et al. | Oct 2019 | A1 |
20190307612 | Hartwell et al. | Oct 2019 | A1 |
20190307934 | Allen et al. | Oct 2019 | A1 |
20190314209 | Ha et al. | Oct 2019 | A1 |
20190321509 | Chakravarthy et al. | Oct 2019 | A1 |
20190321526 | Robinson et al. | Oct 2019 | A1 |
20190336641 | Nisbet | Nov 2019 | A1 |
20190336658 | Heaton et al. | Nov 2019 | A1 |
20190336739 | Locke et al. | Nov 2019 | A1 |
20190343979 | Kearney et al. | Nov 2019 | A1 |
20190343993 | Weston | Nov 2019 | A1 |
20190343994 | Greener | Nov 2019 | A1 |
20190350763 | Pratt et al. | Nov 2019 | A1 |
20190350765 | Heagle et al. | Nov 2019 | A1 |
20190351111 | Locke et al. | Nov 2019 | A1 |
20190358361 | McInnes et al. | Nov 2019 | A1 |
20190374408 | Robles et al. | Dec 2019 | A1 |
20190374673 | Hoefinghoff et al. | Dec 2019 | A1 |
20190380881 | Albert et al. | Dec 2019 | A1 |
20190380882 | Taylor et al. | Dec 2019 | A1 |
20190380883 | MacPhee et al. | Dec 2019 | A1 |
20190381222 | Locke et al. | Dec 2019 | A9 |
20190388577 | Chandrashekhar-Bhat et al. | Dec 2019 | A1 |
20190388579 | MacPhee et al. | Dec 2019 | A1 |
20190388589 | MacPhee et al. | Dec 2019 | A1 |
20200022844 | Blott et al. | Jan 2020 | A1 |
20200023103 | Joshi et al. | Jan 2020 | A1 |
20200030499 | Menon et al. | Jan 2020 | A1 |
20200038023 | Dunn | Feb 2020 | A1 |
20200038639 | Patel et al. | Feb 2020 | A1 |
20200046565 | Barta et al. | Feb 2020 | A1 |
20200046568 | Sexton | Feb 2020 | A1 |
20200061254 | Joshi et al. | Feb 2020 | A1 |
20200069835 | Hissink et al. | Mar 2020 | A1 |
20200069851 | Blott et al. | Mar 2020 | A1 |
20200078225 | Grillitsch et al. | Mar 2020 | A1 |
20200085626 | Braga et al. | Mar 2020 | A1 |
20200085630 | Robinson et al. | Mar 2020 | A1 |
20200100945 | Albert et al. | Apr 2020 | A1 |
20200113741 | Rehbein et al. | Apr 2020 | A1 |
20200114049 | Wall | Apr 2020 | A1 |
20200129675 | Robinson et al. | Apr 2020 | A1 |
20200138754 | Johnson | May 2020 | A1 |
20200139023 | Haggstrom et al. | May 2020 | A1 |
20200146894 | Long et al. | May 2020 | A1 |
20200155379 | Shaw et al. | May 2020 | A1 |
20200170843 | Collinson et al. | Jun 2020 | A1 |
20200171197 | Hubbell et al. | Jun 2020 | A1 |
20200254139 | Phillips et al. | Aug 2020 | A1 |
20200261275 | Manwaring et al. | Aug 2020 | A1 |
20200276055 | Randolph et al. | Sep 2020 | A1 |
20200297894 | Koyama et al. | Sep 2020 | A1 |
20200299865 | Bonnefin et al. | Sep 2020 | A1 |
20200306091 | Lee et al. | Oct 2020 | A1 |
20200315854 | Simmons et al. | Oct 2020 | A1 |
20200330283 | Locke et al. | Oct 2020 | A1 |
20200330284 | Locke et al. | Oct 2020 | A1 |
20200337719 | Ingram et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
1307489 | Aug 2001 | CN |
0525062 | Feb 1993 | EP |
2000510539 | Aug 2000 | JP |
2003510475 | Mar 2003 | JP |
2006110393 | Apr 2006 | JP |
2008518726 | Jun 2008 | JP |
2008529618 | Aug 2008 | JP |
2011504127 | Feb 2011 | JP |
WO-9116490 | Oct 1991 | WO |
WO-9312275 | Jun 1993 | WO |
WO-9519795 | Jul 1995 | WO |
WO-1998-046818 | Oct 1998 | WO |
WO-1999-064080 | Dec 1999 | WO |
WO-2000-001425 | Jan 2000 | WO |
WO-2001-023653 | Apr 2001 | WO |
2005013543 | Mar 2005 | WO |
WO-2006052839 | May 2006 | WO |
WO-2006087021 | Aug 2006 | WO |
WO-2010085426 | Jul 2010 | WO |
WO-2010122665 | Oct 2010 | WO |
WO-2011077096 | Jun 2011 | WO |
2011121394 | Oct 2011 | WO |
2011135284 | Nov 2011 | WO |
2011144888 | Nov 2011 | WO |
2013015827 | Jan 2013 | WO |
WO-2013079947 | Jun 2013 | WO |
WO-2013079949 | Jun 2013 | WO |
2013126049 | Aug 2013 | WO |
2014014842 | Jan 2014 | WO |
2015145117 | Oct 2015 | WO |
2015173546 | Nov 2015 | WO |
Entry |
---|
Australian Patent Application No. 2012343581 Examiner's Second Report dated Jun. 27, 2016. |
Australian Patent Application No. 2012343583 Patent Examination Report No. 1 dated Aug. 10, 2016. |
Chinese Patent Application No. 201280068356.8 First Office Action dated Jun. 8, 2015. |
Chinese Patent Application No. 201280068356.8 Second Office Action dated Apr. 18, 2016. |
Chinese Patent Application No. 201280068502.7 First Office Action dated Sep. 6, 2015. |
Chinese Patent Application No. 201280068502.7 Second Office Action dated Jun. 15, 2016. |
Colombia Patent Application No. 14-139575-8 Writ dated Jun. 1, 2016. |
Columbia Patent Application No. 14-139580 Writ dated Jun. 1, 2016. |
PCT/GB2012/052950 International Preliminary Report on Patentability dated Jun. 3, 2014. |
PCT/GB2012/052952 International Preliminary Report on Patentability dated Jun. 3, 2014. |
PCT/GB2012/052952 International Search Report dated Mar. 1, 2013. |
U.S. Appl. No. 14/362,050 Office Action dated Apr. 29, 2015. |
U.S. Appl. No. 14/362,050 Office Action dated Feb. 10, 2016 |
Karamuk, E., et al., “TISSUPOR: Development of a structured wound dressing based on a textile composite functionalised by embroidery technology,” KTI. Projekt No. 511, (2001), XP55054592, available from: URL:http://www.tissupor.com/pdf/tissupor_kti.pdf. |
PCT-GB-2012-052950 International Search Report dated Feb. 28, 2013. |
Australian Patent Application No. 2012343583 Examiner's First Report dated Aug. 10, 2016. |
Chinese Patent Application No. 201280068356.8 Third Office Action dated Oct. 25, 2016. |
Chinese Patent Application No. 201280068502.7 Third Office Action dated Feb. 4, 2017. |
Colombia Patent Application No. 14-139575 Writ No. 11665 dated Oct. 19, 2016 (in Spanish) with foreign associate reporting letter dated Nov. 3, 2016 (in English). |
Colombia Patent Application No. 14-139850 Writ dated Oct. 12, 2016. |
European Patent Application No. 12798352.6 Communication dated Aug. 29, 2016. |
Japanese Patent Application No. 2014-543971 Office Action dated Nov. 29, 2016. |
Japanese Patent Application No. 2014-543972 Office Action dated Dec. 20, 2016. |
New Zealand Patent Application No. 626695 Further Examination Report dated Sep. 9, 2016. |
New Zealand Patent Application No. 723782 Examiner's First Report dated Sep. 9, 2016. |
Chinese Patent Application No. 201280028356.8 Office Action dated May 26, 2017. |
Columbia Patent Application No. 14139575 Resolution No. 28622 dated May 23, 2017. |
Guha et al., Predicting yarn tenacity: A comparison of mechanistic, statistical, and neural network models. The Journal of Textile Institute, 92(Issue 2, Parts 1 and 2):4 pages, 2001. Abstract. |
Ramey et al., Relationship of cotton fiber properties to yarn tenacity. Textile Research Journal, 2 pages, Jul. 2, 2016. Abstract. |
Japanese Patent Application No. 2014-543971 Office Action dated Aug. 1, 2017. |
Chinese Patent Application No. 201280068356.8 Office Action dated May 3, 2018. |
European Patent Application No. 18162727.4 Extended European Search Report dated Aug. 6, 2018. |
Japanese Opposition No. 2018-700440 Decision of Opposition to Patent dated Oct. 5, 2018. |
Japanese Opposition No. 2018-700440 Notice of Opposition to Patent dated May 30, 2018. |
Korean Patent Application No. 10-2014-7017863 Office Action dated Aug. 10, 2018. |
Number | Date | Country | |
---|---|---|---|
20140323999 A1 | Oct 2014 | US |